Hexima to attend ASM Microbe 2016

Hexima’s Chief Science Officer, Professor Marilyn Anderson, and Onychomycosis Project Leader, Dr Michael Baker, will attend ASM Microbe 2016, held in Boston in June, to present Hexima’s antifungal technology. The conference will be an opportunity to showcase the...

Board and Management Update

The Board is pleased to advise shareholders of changes to the Company’s Board and to the management structure of Hexima.  Please click on the link below for details. Hexima Board and Management Update Dec...

August 2015 Shareholder Update

As reported in Hexima’s previous letter to shareholders, the board considers the company now has a real opportunity to make a significant return to shareholders in the intermediate term (one to three years) from its onychomycosis program.  This Shareholder...